MARKETS / NASDAQ / SMTI
NASDAQ · ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES · SMALL CAP

Sanara Medtech Inc. SMTI

16 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$103.1M
▲ 19.0% vs FY2024
EPS · FY25
$-4.36
Dividend / sh · FY25
Payout · FY25
ROE · FY25
-165.7%
Net margin · FY25
-36.4%
Dividend coverage
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 103.1M
Revenue, FY2025 · full 16-year series below
Revenue Net income
0.040.080.120.1-0.0201020132016201920222025
0.040.080.120.1-0.02016201920222025

The company lost 36 cents on every revenue dollar this year.

Per share
USD -4.36
Diluted EPS, FY2025
EPS
0.40.81.2-4.36201020132016201920222025
0.40.81.2-4.362016201920222025

The company pays no cash dividend.

Profitability
-165.7%
Return on equity, FY2025
ROE
0.250.50.751-165.7%201020132016201920222025
0.250.50.751-165.7%2016201920222025
Operating margin7.1%
Net margin-36.4%
Return on assets-46.7%

Each USD of equity lost 166 cents this year.

Returned to shareholders
returned in FY2025 · dividends + net buybacks
Dividends paid
Net buybacks
Share of profit
Consecutive raises

Growth
+45.9% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+31.0%
+45.9%
+40.8%
+37.1%

Compound annual rates per period — left blank where the series crosses a loss.

Share base
0.01B
Shares outstanding, FY2025
0.040.01201020132016201920222025
0.110.012016201920222025
Change, 5 years+42.1%
Change, 10 years

The share count grew 42% in five years — the same company, cut into more, smaller slices.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 72.9M
total assets, end of FY2025
Total assetsUSD 72.9M
EquityUSD 5.9M
CashUSD 16.6M
Gross debtUSD 46.0M
Net debtUSD 29.4M
Current ratio1.80×

Net debt stands at 495% of equity.

History
16 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
0.1
0.1
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
·
·
−0.0
−0.0
−0.0
EBITDA $B
0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
·
·
·
·
−0.0
−0.0
−0.0
Income tax $B
·
0.0
·
−0.0
·
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−4.36
−1.14
−0.52
−1.00
−1.08
−0.76
−1.32
0.00
0.00
−0.01
−0.02
−0.03
−0.05
−0.03
−0.23
−0.19
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−165.7
−22.9
−9.9
−21.9
−43.1
−69.6
−78.2
−174.2
·
·
·
·
·
·
·
−1190.7
Shares out B
0.01
0.01
0.01
0.01
0.01
0.01
0.00
0.00
0.11
0.11
0.11
0.09
0.09
0.07
0.06
0.04

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
62 of 62
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 0 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed